



Press Release

TecPort Vision and Avulux Venture Partner Get FDA Greenlight to Enter the US Migraine Market

June 15th, 2022 — Tam Le, Founder and Chairman of Tecport Vision, a company based in Orlando, Florida, announced today that the FDA has allowed the health claims associated with its patented optical lenses that capitalize on the science of light waves to alleviate symptoms in light-sensitive migraine sufferers. The optical lenses were developed in conjunction with leading University of Utah scientists and are available exclusively under the Avulux brand. The Avulux brand is the only scientifically proven, non-pharmaceutical lens option that effectively filters out blue, amber and red wavelengths of light, which have been shown to trigger or worsen migraine attacks.

“We are grateful to our Vice-Chairman, Dr. Nabil El-Hag, the visionary architect and driving force behind our joint venture aimed at bringing our technology to the US market,” said Mr. Le. According to the MIGRAINE RESEARCH FOUNDATION, about 12% of the US population suffers from migraines.

“The FDA greenlight is the culmination of a nine-year journey with world renowned scientists and business leaders. It’s been an honor to shepherd this technology through the clinical and business development process. The ability of Avulux migraine glasses to provide a safer, less invasive way to alleviate the symptoms associated with light sensitive migraines will be a game changer for doctors and patients alike,” commented Dr. El-Hag.



TecPort Venture Partners (left to right):
Rich Sholtz, RPh., Esq, Tam Le and Dr. Nabil El-Hag

For more information visit www.tecportvision.com and www.avulux.com